Novel molecular and cellular approaches for alcoholism medication development

这项为期五年的酒精相关研究计划项目资助提案通过汇集具有分子生物学，电生理学和行为学专业知识的经验丰富的酒精研究人员，为治疗酒精中毒的药物开发提供了创新范例。我们的目标是开发必要的技术和合作，以确定药物开发的新靶点，并将我们对酒精靶点的了解转化为选择性配体。PPG包括管理核心（Adron Harris，PI和中心主任），使用噬菌体展示鉴定和表征离子通道的特异性变构调节剂（S。John Mihic和Rick Morrisett），酒精奖励中新型治疗靶点的分子和细胞机制（Igor Ponomarev和Hitoshi Morikawa），药物开发的microRNA靶点（Dayne Mayfield）和动物核心（Yuri Blednov和Rueben冈萨雷斯），为项目提供小鼠和行为测试。PPG拥有内部和外部咨询委员会成员，由在药物开发和治疗方面具有广泛专业知识的科学家提供专家指导。

This five-year funding proposal for a Program Project Grant on alcohol-related research provides innovative paradigms for medication development for the treatment of alcoholism by bringing together experienced alcohol researchers with expertise in molecular biology, electrophysiology and behavior. The goal is to develop the technologies and collaborations necessary to define new targets for medication development and translate our knowledge of alcohol targets into selective ligands. The PPG consists of an Administrative Core (Adron Harris, PI and Center Director), identification and characterization of specific allosteric modulators of ion channels using phage display (S. John Mihic and Rick Morrisett), molecular and cellular mechanisms of novel therapeutic targets in alcohol reward (Igor Ponomarev and Hitoshi Morikawa), microRNA targets for medication development (Dayne Mayfield) and an animal core (Yuri Blednov and Rueben Gonzales) to provide mice and behavioral testing to the projects. The PPG has both internal and external advisory board members, providing expert guidance from scientists with a wide range of expertise in drug development and therapeutics.